Request Demo

Last update 23 Jan 2025

Ramucirumab

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Ramucirumab (Genetical Recombination), Ramucirumab (USAN), Ramucirumab (genetical recombination) (JAN)

+ [11]

Target

VEGFR2

Mechanism

VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [3]

Active Indication

Unresectable Hepatocellular CarcinomaAdvanced gastric carcinomaMetastatic Gastric Carcinoma+ [40]

Inactive Indication

Advanced Esophageal Squamous Cell CarcinomaAdvanced Gastric AdenocarcinomaAdvanced Hepatocellular Carcinoma+ [36]

Originator Organization

Dyax Corp.

Active Organization

Eli Lilly & Co.

Innovent Biologics, Inc.Eli Lilly Nederland BV

+ [4]

Inactive Organization

Lilly Asia Shanghai Representative Office

Innovent Biologics (Suzhou) Co. Ltd.

Celgene Corp.

Drug Highest PhaseApproved

First Approval Date

US (21 Apr 2014),

Gastroesophageal junction adenocarcinomaStomach Cancer

RegulationFast Track (US), Orphan Drug (US)

Structure/Sequence

Sequence Code 9107105H

Source: *****

Sequence Code 9583823L

Source: *****

227

Clinical Trials associated with Ramucirumab

NCT06675136

/ Not yet recruitingPhase 1IIT

Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

Start Date17 Oct 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06616584

/ Not yet recruitingPhase 2/3IIT

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Start Date11 Jul 2025

Sponsor / Collaborator

SWOG

[+2]

NCT06771622

/ Not yet recruitingPhase 1/2

Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination with Multiple Agents in Subjects with Advanced Solid Tumors

This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK profile, and preliminary efficacy of HCB101 in combination therapies in subjects with advanced solid tumors. The trial consists of four cohorts, each including a part I of the dose-escalation phase (Phase Ib) and a part II of the dose-expansion phase (Phase IIa).

Start Date31 Jan 2025

Sponsor / Collaborator

HanchorBio inc

100 Clinical Results associated with Ramucirumab

100 Translational Medicine associated with Ramucirumab

100 Patents (Medical) associated with Ramucirumab

1,414

Literatures (Medical) associated with Ramucirumab

01 Dec 2025·Journal of Gastrointestinal Cancer

Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab

Review

Author: Gupta, Palvi ; Taipale, Kaisa ; Goel, Rajat ; Earley-Valovic, Veronika ; D'yachkova, Yulia ; Paine, Abby ; Liepa, Astra M

PURPOSEWith relatively few direct comparisons among treatment options for previously treated advanced gastric cancer or gastroesophageal junction (GEJ) cancer, network meta-analysis (NMA) may inform evidence-based decision-making. Ramucirumab plus paclitaxel (RAM + PTX) is a preferred regimen in guideline recommendations. NMA of key outcomes may further characterize the relative clinical value of RAM + PTX.METHODSA systematic literature review of randomized controlled trials of adult patients with previously treated advanced gastric/GEJ cancer informed a NMA which compared overall survival, progression-free survival, and discontinuations due to adverse events. Comparisons were reported relative to placebo/best supportive care (BSC) when possible, otherwise relative to RAM + PTX.RESULTSThe base-case NMA focused on second-line treatment only, from 19 of 28 studies identified. For overall survival, seven of 16 regimens were favorable relative to placebo/BSC, with RAM + PTX as the most favorable. For progression-free survival, five of 14 regimens were unfavorable relative to RAM + PTX. For discontinuations due to adverse events, two of 13 regimens were similar to placebo/BSC: ramucirumab monotherapy and fluorouracil; relative to RAM-PTX, all regimens were similar except ramucirumab monotherapy which was favorable and irinotecan + cisplatin which was unfavorable.CONCLUSIONThis NMA of trials of previously treated gastric/GEJ cancer suggests that RAM + PTX has one of the more favorable clinical profiles.

15 Jan 2025·Internal Medicine

Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors

Article

Author: Yamada, Hideharu ; Takenaga, Noriko ; Shirota, Hidekazu ; Ishioka, Chikashi ; Saijo, Ken ; Taniguchi, Sakura ; Kawamura, Yoshifumi ; Ouchi, Kota ; Umegaki, Sho ; Komine, Keigo ; Imai, Hiroo ; Takahashi, Masanobu ; Sasaki, Keiju ; Yoshida, Yuya ; Kasahara, Yuki

Objective Many vascular endothelial growth factor (VEGF) pathway inhibitors are used in the treatment of patients with various advanced cancers; however, treatments induce cardiovascular adverse events (CVAEs), such as hypertension, heart failure, arrhythmia, arterial or venous embolism, and hemorrhage. Some studies have suggested a correlation between efficacy and CVAEs; however, further evidence is required. This study evaluated real-world data concerning the frequency and degree of CVAEs and possible associations between CVAEs and efficacy in such patients. Methods We analyzed CVAEs observed in 294 patients with advanced cancer who were treated with ramucirumab, regorafenib, pazopanib, sunitinib, or sorafenib. Results CVAEs of any grade and proteinuria within 8 weeks after the initiation of VEGF pathway inhibitors (early) or during the treatment period (total period) were observed in 72-85% and 77-92% of the patients, respectively. The progression-free survival (PFS) of patients with a CVAE of grade ≥1 in the early period was favorable compared with the PFS of those who had no CVAE (median, 4.9 vs. 3.5 months, p=0.016, log-rank test). Furthermore, the PFS of patients with a CVAE grade ≥3 in the early period was favorable compared to that of those with CVAEs of grades 0-2. Taken together, a higher degree of CVAE was correlated with favorable patient outcomes. Conclusion This study revealed the frequency and degree of CVAEs in patients with solid cancers who received VEGF pathway inhibitors in a real-world setting and added evidence regarding the correlation between CVAEs and efficacy of VEGF pathway inhibitors.

01 Jan 2025·Critical Reviews in Oncology/Hematology

Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials

Review

Author: Wang, Wanning ; Cai, Jing ; Bai, Yuansong ; Zhang, Wenlong ; Cong, Dan

HER2-positive gastric cancer (GC), a unique molecular subtype, has garnered significant interest in recent years. Here, we review clinical trial data on advanced HER2-positive GC from the past 15 years. Trastuzumab plus standard chemotherapy remain the first-line treatment. The initial survival benefits conferred by immune checkpoint inhibitors plus trastuzumab and standard chemotherapy are encouraging. The combination of ramucirumab and mono-chemotherapy, as well as the antibody conjugated drug trastuzumab deruxtecan, is the recommended second-line regimen. Treatment with immune checkpoint inhibitors plus ramucirumab and mono-chemotherapy shows promise. Despite the limited treatment options for third line and beyond, development of novel therapeutic strategies is expected. Although clinical cure of advanced HER2-positive GC is unlikely, current clinical studies offer valuable insight into regimens that prolong survival.

184

News (Medical) associated with Ramucirumab

13 Jan 2025

·www.prnewswire.com

Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones

-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 -- -- Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an Investigational New Drug (IND) application in 2026 -- BOSTON, Jan. 13, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones. "We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings. With our Phase 1 clinical trial ongoing and now enrolling both monotherapy and combination cohorts, we are in a leading position to explore the compelling potential of EO-3021, our differentiated Claudin 18.2 ADC, to improve outcomes for people living with advanced gastric/GEJ cancer." Mr. Ferra continued, "We look forward to sharing additional data from our Phase 1 dose escalation and expansion study of EO-3021 in the first half of 2025. With this readout, we aim to build on the promising initial data reported in August 2024, reinforcing EO-3021's robust anti-tumor activity and potential better combinability, while garnering additional insights to inform our go-forward clinical development efforts. We are enthusiastic about the potential of EO-3021 in addressing meaningful market opportunities and look forward to a transformative 2025." Program Updates and Upcoming Milestones EO-3021: Elevation Oncology is developing EO-3021, a differentiated, potentially best-in-class antibody drug conjugate (ADC) for the treatment of patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric/GEJ cancer. In August 2024, Elevation Oncology reported promising initial monotherapy data from the dose escalation portion of its ongoing Phase 1 clinical trial of EO-3021, demonstrating competitive efficacy, with a 42.8% confirmed overall response rate (ORR) in a biomarker-enriched population, and a differentiated safety profile, including minimal hematological toxicity and hepatotoxicity, and no peripheral neuropathy/hypoesthesia. Based on these data, Elevation Oncology is focusing the clinical development of EO-3021 on the first- and second-line treatment of advanced gastric/GEJ cancer, where EO-3021's key attributes can potentially provide differentiated benefits and address unmet needs in both patient outcomes and safety. Monotherapy : The dose expansion portion of Elevation Oncology's Phase 1 clinical trial of monotherapy EO-3021 is ongoing. As of January 2025, Elevation Oncology has implemented prospective Claudin 18.2 expression testing as part of the patient screening process, focusing enrollment on patients with ≥25% of tumor cells at IHC 1+/2+/3+. Elevation Oncology expects to report additional safety and efficacy data from the dose escalation and expansion portions of the study in the first half of 2025. Combination: Patient dosing is ongoing in the combination portion of Elevation Oncology's Phase 1 clinical trial of EO-3021. The combination cohorts are evaluating EO-3021 in combination with dostarlimab, a PD-1 inhibitor, in the first line setting and with ramucirumab, a VEGFR2 inhibitor, in the second line setting. By combining EO-3021 and dostarlimab, an immune checkpoint inhibitor, Elevation Oncology aims to deliver synergistic benefit, potentially offering patients improved outcomes beyond those seen with the existing combination of immunotherapy and chemotherapy. The combination of an immunotherapy and chemotherapy agent is the standard of care for the treatment of gastric/GEJ cancer in the front-line setting. With the EO-3021 and ramucirumab combination, Elevation Oncology aims to deliver improved tolerability and synergistic anti-tumor activity compared to the approved combination of ramucirumab and paclitaxel. The combination of ramucirumab and paclitaxel is the standard of care for the treatment of second-line gastric/GEJ cancer. Elevation Oncology expects to report initial data from the combination cohorts in the fourth quarter of 2025 or the first quarter of 2026. EO-1022: Elevation Oncology is developing EO-1022, a differentiated HER3 ADC for the treatment of patients with HER3-expressing solid tumors, including breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer. EO-1022 combines seribantumab, a fully human anti-HER3 monoclonal antibody, and a monomethyl auristatin E (MMAE) payload with site-specific conjugation to glycan. It is designed to leverage seribantumab's desirable internalization capability and the latest site-specific ADC technology to deliver a safe, effective option for patients living with solid tumors that express HER3. Elevation Oncology expects to present preclinical data for EO-1022 in the first half of 2025 and to file an IND application in 2026. Financial Guidance Elevation Oncology expects that its cash, cash equivalents and marketable securities as of September 30, 2024, will be sufficient to fund its current operations into 2026. About Elevation Oncology, Inc. Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our ADC expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in a Phase 1 trial (NCT05980416) as a monotherapy, and in combinations with dostarlimab or ramucirumab, in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. We are also advancing EO-1022, a HER3 ADC for the treatment of patients living with solid tumors that express HER3, through preclinical development. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of clinical and preclinical results, potential benefits of product candidates, potential market opportunities for product candidates, the ability of product candidates to treat their targeted indications and Elevation Oncology's expectations about its cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Elevation Oncology Investor and Media Contact Gracie Tong Senior Director, Investor Relations and Corporate Communications [email protected] SOURCE Elevation Oncology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1ImmunotherapyADCClinical Result

03 Jan 2025

·ir.alxoncology.com

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The updated results from the ASPEN-06 study will be detailed in the following oral presentation: Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)Abstract Number: 332Presenter: Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in JapanPresentation Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PSTSession Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and StomachLocation: Level 2 Ballroom Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting. About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology cdoherty@alxoncology.com (650) 466-7125 Media Contact: Audra Friis, Sam Brown, Inc. audrafriis@sambrown.com (917) 519-9577

ASCOPhase 2ImmunotherapyClinical Result

17 Dec 2024

·www.echemi.com

Eli Lilly’s Pirtobrutinib Joins the Race as BTK Competition Heats Up

On December 16, Innovent Biologics and Eli Lilly announced a collaboration agreement for the non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, pirtobrutinib, in mainland China. Under this agreement, Innovent Biologics will handle the import, sales, promotion, and distribution, while Eli Lilly will manage R&D and post-market medical affairs. On October 29, Eli Lilly’s pirtobrutinib received approval from the National Medical Products Administration (NMPA) for treating relapsed or refractory mantle cell lymphoma (MCL) in adults who have previously received BTK inhibitor treatments. Currently, the domestic market has five approved BTK inhibitors, including ibrutinib, zanubrutinib, ocatabrutinib, and acabrutinib. Sanofi’s Tolebrutinib and Rilzabrutinib are in Phase III clinical trials, while CT-1530 from Shouyao Holdings is in Phase II. The robust development of BTK inhibitors indicates potential market changes. BTK inhibitors work by targeting the BCR signaling pathway, binding to BTK, inhibiting its phosphorylation, and inducing apoptosis, effectively managing B-cell malignancies. Before BTK inhibitors, lymphoma treatments were limited to chemotherapy, anti-CD20 antibodies, and radiotherapy. Ibrutinib, the first BTK inhibitor, revolutionized B-cell cancer treatment since its 2013 debut and was approved in China in 2017. However, sales of ibrutinib have slowed due to competition from similar drugs. Zanubrutinib, developed by BeiGene, reached $1.297 billion in global sales in 2023, marking the first domestic drug to achieve such success, but it now faces increasing competition. Pirtobrutinib, as the first and only non-covalent BTK inhibitor, intensifies competition in this niche market. It shows potential to overcome resistance to covalent BTK inhibitors and offers a new option for relapsed/refractory MCL patients. To highlight its efficacy, Eli Lilly conducted a head-to-head study in the BRUIN MCL-321 trial. By 2030, pirtobrutinib is projected to capture 60% of the chronic lymphocytic leukemia market, equating to $3 billion in annual sales. With advancing technology and new drug development, the BTK market is expanding rapidly. According to Frost & Sullivan, the global BTK market could reach $20 billion by 2025 and $26.1 billion by 2030. In China, the market size is expected to reach RMB 13.1 billion by 2025 and RMB 22.5 billion by 2030. The growing BTK market has attracted numerous pharmaceutical companies. At least 20 BTK inhibitors are in clinical trials domestically, with Shouyao Holdings, Hengrui Medicine, and Hezheng Pharmaceutical leading the way. Ibrutinib’s core patent will expire on December 28, 2026, and at least 10 companies are preparing generics. This will lead to fierce competition among original drugs, domestic innovations, and generics. BeiGene’s zanubrutinib remains a key product, but new competitors like pirtobrutinib pose challenges. The success of pirtobrutinib in China’s market is worth monitoring. Originally developed by Redx Pharma and acquired by Loxo Oncology, pirtobrutinib was purchased by Eli Lilly for $8 billion in 2019. In March 2022, Innovent Biologics secured Chinese commercialization rights for pirtobrutinib with an initial payment of $45 million. The partnership between Innovent Biologics and Eli Lilly began in 2015 and has expanded through multiple projects. Despite setbacks like sintilimab’s rejection by the U.S. FDA in 2022, their collaboration continues with other initiatives. Their 2019 cooperation on IBI362, a dual GLP-1R and GCGR agonist, is in Phase II/III trials for Type 2 diabetes and weight loss. In March 2022, Eli Lilly’s ramucirumab was approved in China, granting Innovent Biologics exclusive commercialization rights. Additionally, they collaborate on selpercatinib, a RET inhibitor for gene fusion tumors. The cooperation and competition between domestic and multinational pharmaceutical companies are becoming a norm. This model offers a win-win strategy for navigating the global market.

Drug ApprovalAcquisitionPhase 3Phase 2License out/in

100 Deals associated with Ramucirumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09371	Ramucirumab	L01XC21	DB05578

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Colorectal Cancer	NO	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	IS	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	LI	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	EU	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	NO	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	LI	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	IS	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	EU	Eli Lilly Nederland BV	19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction	EU	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	LI	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	EU	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	NO	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	IS	Eli Lilly Nederland BV	19 Dec 2014
Non-Small Cell Lung Cancer	LI	Eli Lilly Nederland BV	19 Dec 2014
Non-Small Cell Lung Cancer	EU	Eli Lilly Nederland BV	19 Dec 2014
Non-Small Cell Lung Cancer	NO	Eli Lilly Nederland BV	19 Dec 2014
Non-Small Cell Lung Cancer	IS	Eli Lilly Nederland BV	19 Dec 2014
metastatic non-small cell lung cancer	US	Eli Lilly & Co.	12 Dec 2014
Gastroesophageal junction adenocarcinoma	US	Eli Lilly & Co.	21 Apr 2014
Stomach Cancer	US	Eli Lilly & Co.	21 Apr 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-negative breast cancer	Phase 2	RU	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	IE	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	LB	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	ES	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	IL	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	BE	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	HR	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	EG	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	NZ	Eli Lilly & Co.	06 Aug 2008
HER2-negative breast cancer	Phase 2	PE	Eli Lilly & Co.	06 Aug 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02581215 (HCRN GI14-198, CTgov)	Phase 2	Pancreatic Cancer	84	mFOLFIRINOX+Ramucirumab (Arm A: Experimental Arm)	mlekldbkwo(jwklktropz) = jzvoifkpcs wdtdzvrxpv (gvsttizjac, kgolewtesi - mprroozqpj) View more	-	01 Jan 2025
				mFOLFIRINOX (Arm B: Placebo Arm)	mlekldbkwo(jwklktropz) = ukykeoyegz wdtdzvrxpv (gvsttizjac, ekcgqjlikr - ppauwsldgk) View more
ESMO_ASIA2024 Manual	Not Applicable	Metastatic Colorectal Carcinoma Second line	95	FOLFIRI+Bevacizumab	(omsivnytig) = fohhflmcfs fabadxbjio (eeeulxxdxw ) View more	Positive	07 Dec 2024
				FOLFIRI+Ramucirumab	(omsivnytig) = krfhfghrgz fabadxbjio (eeeulxxdxw ) View more
REAL-SPEED (ESMO_ASIA2024)	Not Applicable	EGFR-mutated non-small Cell Lung Cancer EGFR L858R mutation	168	Ramucirumab plus Erlotinib (RAM+ERL)	ylhmhqemub(fmavuekcse) = notable oieiqgdffr (dgfaqcxgmh ) View more	Positive	07 Dec 2024
NCT03909334 (RAMOSE \| HCRN LUN-18-335, Pubmed \| J Clin Oncol) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer	139	Osimertinib Ramucirumabrumab	(tznyyxqock) = rxfhdwfuuc dsjicenarj (qgvrmobvxk ) View more	Positive	08 Oct 2024
				Osimertinib	(tznyyxqock) = eiseexzadt dsjicenarj (qgvrmobvxk ) View more
NCT04340882 (ESMO2024) Manual	Phase 2	Non-Small Cell Lung Cancer Second line	15	Docetaxelramucirumabpembrolizumab	(lykqyttmht) = fuqcwwmsqs svvjlsdldz (haprutbwkp, 5.4 - NE) View more	Positive	14 Sep 2024
ESMO2024 Manual	Not Applicable	Non-Small Cell Lung Cancer Third line \| Second line	173	Docetaxel with Nintedanib (D+N)	(zlecypamoj) = hxfsxtehew uvtlahdgfw (dclunfbwkc ) View more	Negative	14 Sep 2024
				Docetaxel with Ramucirumab (D+R)	(zlecypamoj) = gvvpwocunz uvtlahdgfw (dclunfbwkc ) View more
JPRN-jRCTs041180166 (WJOG9216G (RECAST), ESMO2024) Manual	Phase 2	Metastatic Colorectal Carcinoma First line	122	FOLFOXIRI pluRAMAM	(zuaucvagpt) = hwelimkymf haeqgzfxtg (iccgeyxtfx, 26.8 - 36.5)	Negative	14 Sep 2024
				8 cycles of FOLFOXIRI plus RAM followed by 5-FU/l-leucovorin plus RAM	(zuaucvagpt) = xphczutlxn haeqgzfxtg (iccgeyxtfx, 21.9 - 31.2)
EUCTR2017-001207-68-DE (RamuNET, ESMO2024) Manual	Phase 2	Pancreatic neuroendocrine tumour metastatic	45	Ramucirumab + dacarbazine	(fflsbhbkng) = ynqsdwmopj uffereuhrw (evbwwihuov ) View more	Positive	13 Sep 2024
NCT05002127 (ASPEN-06, Company_Website) Manual	Phase 2/3	HER2-positive gastric cancer \| HER2 positive Gastroesophageal Junction Adenocarcinoma	127	Evorpacept + trastuzumab + CYRAMZA + paclitaxel	(ljtsjsapuw) = vopznntvbj ywbzlglqfp (azpwgwmjku ) View more	Positive	31 Jul 2024
				Trastuzumab + CYRAMZA + paclitaxel	(ljtsjsapuw) = jsdtrzcziz ywbzlglqfp (azpwgwmjku ) View more
NCT02443324 (JVDF, CTgov)	Phase 1	Adenocarcinoma \| Urothelial Carcinoma of the Urinary Bladder \| Locally Advanced Gastroesophageal Junction Adenocarcinoma \| stomach adenocarcinoma \| Non-Small Cell Lung Cancer \| Biliary Tract Neoplasms	175	pembrolizumab+Ramucirumab (Cohort A)	slyagmqwkt(fwqhidtxww) = ytqcepkvfo vkdhcwagfm (fjlvwevcje, laszgckcsv - rfasfxlxef) View more	-	31 Jul 2024
				pembrolizumab+Ramucirumab (Cohort C)	slyagmqwkt(fwqhidtxww) = gjqagxpozp vkdhcwagfm (fjlvwevcje, tlokyussam - buhlrfgssu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis